Abstract
The in vivo effects of dexamethasone administration on liver and extrahepatic tissue carnitine concentrations were assessed in 48-h-starved rats. In heart and kidney, but not in liver, dexamethasone significantly increased total carnitine concentration. Acute (2.5 h) treatment with 2-tetradecylglycidate (TDG), a specific inhibitor of carnitine palmitoyl transferase 1, not only increased total hepatic carnitine concentrations, but also permitted an effect of dexamethasone (a further increase in hepatic carnitine concentration). The results are discussed in terms of acute (substrate-mediated) and chronic (hormonal) control of carnitine turnover.
Similar content being viewed by others
References
Brass EP & Hoppel CL (1978) J. Biol. Chem.253, 2688–2693.
Bremer J (1983) Physiol. Rev.63, 1420–1480.
Huth PJ & Shug AL (1980) Biochim. Biophys. Acta602, 621–634.
Kraus-Friedmann N (1984) Physiol. Rev.64, 170–259.
Mannaerts GP & Debeer LJ (1981) Beta-oxidation of fatty acids: relative contribution of mitochondria and peroxisomes. In:Short-Term Regulation of Liver metabolism (Hue L & Van de Werve G, eds), pp 273–290, Elsevier-North Holland Biomedical Press.
Mölstad P & Böhmer T (1979) Biochim. Biophys. Acta585, 94–99.
Rebouche CJ & Engel WK (1983) Mayo Clin. Proc.58, 533–540.
Schofield PS, French TJ, Goode AW & Sugden MC (1985) FEBS Lett.184, 214–220.
Vary TC & Neely JR (1983) Am. J. Physiol.244, H247–252.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
French, T.J., Good, A.W., Palmer, T.N. et al. Effects of dexamethasone on carnitine metabolism in liver and extrahepatic tissues. Biosci Rep 5, 729–734 (1985). https://doi.org/10.1007/BF01119870
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01119870